TAILIEUCHUNG - Báo cáo y học: "Seven-year follow-up of infliximab therapy in rheumatoid arthritis patients with severe long-standing refractory disease: attrition rate and evolution of disease activity"

Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học General Psychiatry cung cấp cho các bạn kiến thức về ngành y đề tài: Seven-year follow-up of infliximab therapy in rheumatoid arthritis patients with severe long-standing refractory disease: attrition rate and evolution of disease activity. | Vander Cruyssen et al. Arthritis Research Therapy 2010 12 R77 http content 12 3 R77 RESEARCH ARTICLE Open Access Seven-year follow-up of infliximab therapy in rheumatoid arthritis patients with severe long-standing refractory disease attrition rate and evolution of disease activity Bert Vander Cruyssen 1 Patrick Durez2 Rene Westhovens3 and Filip De Keyser1 Abstract Introduction This study is based on the results from a Belgian expanded access program in which patients with active refractory and erosive rheumatoid arthritis RA were treated with intravenous infusions of infliximab in combination with methotrexate. The objectives of this study were to evaluate the continuation rate of infliximab and its clinical effect over a 7-year period and to document the reasons for discontinuation. Methods Between 2000 and 2001 511 patients with severe and refractory RA were enrolled and treated with infliximab. After 7 years apart from routine clinical follow-up treating rheumatologists were asked to complete a questionnaire designed specifically for the present study to evaluate the current therapy with infliximab the level of disease activity Disease Activity Score in 28 joints DAS28 and the reasons for infliximab discontinuation. Results After 7 years 160 of 511 patients 31 were still on infliximab treatment. The major reasons for infliximab discontinuation included lack of efficacy 104 patients adverse events 107 patients and elective change of therapy 70 patients . The majority of cases of treatment discontinuation for safety reasons occurred during the first 2 years. In contrast discontinuation due to ineffectiveness showed a more constant rate over the 7-year period. Mean DAS for patients still on treatment with infliximab decreased from standard error SE at baseline to SE at year 4 and remained that low until year 7 SE . Low disease activity defined as DAS28 was present in of patients and achieved remission .

TỪ KHÓA LIÊN QUAN
TAILIEUCHUNG - Chia sẻ tài liệu không giới hạn
Địa chỉ : 444 Hoang Hoa Tham, Hanoi, Viet Nam
Website : tailieuchung.com
Email : tailieuchung20@gmail.com
Tailieuchung.com là thư viện tài liệu trực tuyến, nơi chia sẽ trao đổi hàng triệu tài liệu như luận văn đồ án, sách, giáo trình, đề thi.
Chúng tôi không chịu trách nhiệm liên quan đến các vấn đề bản quyền nội dung tài liệu được thành viên tự nguyện đăng tải lên, nếu phát hiện thấy tài liệu xấu hoặc tài liệu có bản quyền xin hãy email cho chúng tôi.
Đã phát hiện trình chặn quảng cáo AdBlock
Trang web này phụ thuộc vào doanh thu từ số lần hiển thị quảng cáo để tồn tại. Vui lòng tắt trình chặn quảng cáo của bạn hoặc tạm dừng tính năng chặn quảng cáo cho trang web này.